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Abstract
Background/Objective: Nicardipine is a calcium channel blocker that has been widely used to control blood pressure in
severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage.
However, accumulating evidence suggests that inflammatory processes in the central nervous system that are mediated by
microglial activation play important roles in neurodegeneration, and the effect of nicardipine on microglial activation
remains unresolved.
Methodology/Principal Findings: In the present study, using murine BV-2 microglia, we demonstrated that nicardipine
significantly inhibits microglia-related neuroinflammatory responses. Treatment with nicardipine inhibited microglial cell
migration. Nicardipine also significantly inhibited LPS plus IFN-c-induced release of nitric oxide (NO), and the expression of
inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Furthermore, nicardipine also inhibited microglial
activation by peptidoglycan, the major component of the Gram-positive bacterium cell wall. Notably, nicardipine also
showed significant anti-neuroinflammatory effects on microglial activation in mice in vivo.
Conclusion/Significance: The present study is the first to report a novel inhibitory role of nicardipine on neuroinflammation
and provides a new candidate agent for the development of therapies for inflammation-related neurodegenerative
diseases.
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Introduction
Microglia play pivotal roles in host defense and tissue repair
processes in the central nervous system [1]. Neuroinflammation
caused by microglial activation have both beneficial and
detrimental consequences in the nervous system [2,3]. During
neuroinflammation, activated microglia leads to clearance of
debris or invading pathogens, and release of neurotrophic factors
that regulate the microenvironment [4]. When sensing ATP leak
from an injury site, microglia transform to a more motile state and
migrate to the site of damage [5], which causes neuroinflammation
and subsequent neurodegeneration [6]. However, hyperactivation
of microglia results in the production of a variety of proin-
flammatory mediators, which have been implicated in the
pathogenesis of several neurodegenerative diseases, including
Alzheimer’s disease [7], Huntington’s disease [8], Parkinson’s
disease [9,10], stroke [11] and hypoxia insults [12]. Microglial
activation involves changes in cell morphology and the subsequent
expression of new proteins, such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2). These proinflammatory
cytokines have been shown to cause neuronal damage [13–16].
Increasing evidence has revealed that iNOS produces a sustained
level of NO [17], and induction of COX-2 expression [18] in
activated microglia which further aggravate the neuropathological
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processes. Previously, iNOS and COX-2produces detrimental
effects in glial cells were also identified in the ischemic
brainhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3498223/
pone.0049701-Yermakova1 [19]. Consistent with this, focal
ischemia-induced brain infarcts and associated neurological
impairments are alleviated in iNOS null mice [20]. The
expressions of the inflammation-related enzymes iNOS and
COX-2 have also been reported in the striatum of Parkinson
disease patients [21]. The expressions of TNF-a and IL-6 have
also been found to be elevated in the brains of Alzheimer’s disease
patients [22,23]. Although inflammatory mediators are necessary
for normal neuronal cell functions, the microglial response must be
tightly regulated to avoid over-activation and neurotoxic conse-
quences [24].
Nicardipine is a dihydropyridine type voltage-sensitive calcium
channel antagonist used in the treatment of vascular disorders.
The mechanism and clinical effects of nicardipine closely resemble
that of the other dihydropyridines. However, nicardipine is more
selective for cerebral and coronary blood vessels and is widely used
to manage severe hypertension after acute brain injury, including
ischemic stroke, traumatic brain injury, and subarachnoid
hemorrhage [25–27]. In clinical practice, nicardipine has also
been used for the treatment of acute hypertension in acute brain
disease, with promising outcomes [26,28–31]. Previous studies also
reported neuroprotective effects of nicardipine on hypertension-
induced brain damage [32–34]. Few animal and human studies
have assessed the beneficial use of nicardipine in acute ischemic
stroke [35]. Notably, nicardipine has also been reported to
regulate calcium signaling in glial cells [36,37]. Previous studies
also reported that the L-type calcium channel blockers verapamil
[38] and nimodipine [39] induce anti-inflammatory effects in
microglia. However, the actual protective and anti-inflammatory
mechanism of nicardipine is unclear. In the present study, we
addressed whether, in addition to controlling blood pressure,
nicardipine also regulates neuroinflammatory responses in mi-
croglia and exerts further neuroprotective effects.
Material and Methods
Ethics statement
The protocol used for the experimental mice was reviewed and
approved by the Institutional Animal Care and Use Committee of
the China Medical University (IACUC approval no. CMU-102-
16N). All animal studies were conducted according to institutional
guidelines (Affidavit of Approval of Animal Use Protocol, No. 102-
16N) approved by the Institutional Animal Care and Use
Committee (IACUC) of China Medical University (Taichung,
Taiwan).
Reagents and antibodies
Recombinant murine IFN-c was purchased from PeproTech
(Rocky Hill, NJ). LPS from Escherichia coli Serotype 055:B5 was
obtained from Sigma-Aldrich (St. Louis, MO). Peptidoglycan from
Staphylococcus aureus was purchased from Fluka (Buchs, Switzer-
land). The antibody against ionized calcium binding adaptor
molecule 1 (Iba 1) was purchased from Wako Pure Chemical
Industries (Osaka, Japan). Primary antibodies against b-actin, p65,
ERK2, phosphorylated ERK1/2, p38, and JNK were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Primary
antibodies against phosphorylated p38, phosphorylated JNK,
and phosphorylated p65 were purchased from Cell Signaling
and Neuroscience (Danvers, MA). The primary antibody against
iNOS was purchased from BD Transduction Lab (Lexington,
KY). The primary antibody against COX-2 was purchased from
Cayman Chemicals (Ann Arbor, MI).
Cell culture
The murine microglial cell BV-2 was originally generated by
infecting primary microglial cell cultures with a v-raf/v-myc
oncogene carrying a retrovirus (J2). BV-2 microglia retain the
morphological, phenotypical, and functional properties of freshly
isolated microglial cells (Blasi et al, 1990). Cells were cultured in
DMEM (Gibco, Grand Island, NY) with 10% FBS at 37uC, and
passaged by trypsinization.
Animals
All mice were manipulated in accordance with the Animal Care
and Use Guidelines of the China Medical University (Taichung,
Taiwan). Male ICR mice were purchased from the National
Laboratory Animal Center (Taipei, Taiwan). The mice were
housed in a temperature- and humidity-controlled environment,
and given free access to foods and water. All studies involving
animals are reported in accordance with the ARRIVE guidelines
(animals in research: reporting in vivo experiments) [40]. Mice
were acclimated to their environment for at least 7 days before
conducting the experiments.
Protocols of treatment
Nicardipine was dissolved in DMSO at 10 mM as stock
solution. The concentrations of nicardipine (1–10 mM) used in
cell culture of this study were according to previous report [41].
Cells were treated with nicardipine or vehicle control for 60 min
and then stimulated with ATP, LPS/IFN-c or peptidoglycan. Cell
migration assay was determined after ATP treatment for 24 h.
Inflammatory mediators were determined by real-time PCR after
LPS plus IFN-c treatment for 6 h. Nitric oxide, iNOS and COX-2
expressions were measured after LPS/IFN-c or peptidoglycan
treatment for 24 h. Phosphorylated protein levels were determined
after LPS/IFN-c treatment for 60 min. In the immunohistochem-
ical and flow cytometry experiments, mice were administered
saline or nicardipine by intraperitoneal injection for 3 consecutive
days. Concentrations of nicardipine administrated to mice were
according to previous study [42]. On the third day, 2 h after the
injection of saline or nicardipine, mice were injected with LPS
intraperitoneally and housed for 24 h before euthanized.
Tissue preparation and immunohistochemistry
Eight-week-old mice received an intraperitoneal injection of
saline or LPS (20 mg/kg) (E. coli, serotype 0127:B8). Twenty-four
hours later, mice were deeply anesthetized with chloral hydrate
and transcardially perfused with 10% formaldehyde. The brains
were dissected and post-fixed overnight, then incubated in a 30%
sucrose solution at 4uC until they sank. Coronal serial sections
(30 mm) were sliced on a freezing sliding microtome cryostat (Leica
CM305S). Endogenous peroxidases in the free-floating slices were
quenched using hydrogen peroxide. Brain sections were blocked
by nonspecific binding with goat serum, permeabilized with Triton
X-100, and then incubated with primary antibodies against Iba-1,
overnight at 4uC. Following incubation with a biotinylated
secondary antibody, the sections were incubated with an avidin-
biotin complex (Vector Laboratories), and labeling was visualized
with diaminobenzidine (DAB). The cerebral cortex, hippocampus
and striatum were digitally captured at 2006magnifications using
a light microscope.
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Flow cytometry
Microglial isolation from mouse brain [43] and flow cytometry
analysis [44,45] were performed according to our previous reports.
Briefly, mice were perfused with a phosphate buffered solution
(PBS). Brains were homogenized in a digestion buffer, then
homogenates were separated by a discontinuous Percoll (GE-
healthcare, Uppsala, Sweden) density gradient (70%, 37%, 30%,
and 0%). The gradient was centrifuged for 40 min at 2006g and
microglia were collected from the interphase between the 70% and
37% Percoll layers.
The surface antigens of microglial cells were assayed by flow
cytometry. Fc receptors were blocked with anti-CD16/CD32
antibody (eBioscience, San Diego, CA) for 30 min at 37uC.
Microglia were incubated with anti-CD11b conjugated to FITC
and anti-CD45 conjugated to peridinin-chlorophyll protein-
cyanine5.5 (PerCP-Cy5.5) antibodies (BD Biosciences, San Jose,
CA). Expression of these surface receptors was determined using a
Becton-Dickinson FACSCaliburTM four-color cytometer (Becton
Dickinson, San Jose, CA). Ten thousand events were recorded and
microglia were identified by CD11b+ and CD45low expression.
Previous report demonstrated that these relative percentages of
cells do not change with LPS [46].
Intracellular IL-6 and TNF-a production by microglia were
determined by intracellular flow cytometric analysis based on a
BD Cytofix/CytopermTM Plus fixation/permeabilization protocol
(BD Biosciences, San Jose, CA). After blocking, cells were stained
with anti-CD11b-FITC and anti-CD45-PerCP-Cy5.5 antibodies.
Next, cells were fixed and permeabilized with BD Cytofix/
CytopermTM solution for 20 min. Cells were washed with BD
Perm/WashTM buffer, re-suspended in BD Perm/WashTM buffer,
and incubated with either anti-IL-6-PE and anti-TNF-a-APC (BD
Biosciences, San Jose, CA) for 30 min. Cells were then washed
twice in BD Perm/WashTM buffer and re-suspended in FACS
buffer.
Western blot analysis
Western blot was performed according to our previous report
[47]. Briefly, cells were lysed in a homogenization buffer for
30 min on ice, and equal amounts of the samples were loaded in
each lane. The membranes were blocked with non-fat milk and
then probed with primary antibodies. After undergoing several
washes, the membranes were incubated with peroxidase-conju-
gated secondary antibodies. The blots were visualized by
enhanced chemiluminescence using Fuji medical X-ray film
(Fujifilm, Tokyo, Japan). The blots were then stripped by
incubation in stripping buffer and reprobed a loading control.
Quantitative data were obtained using a densitometer and Image J
software (National Institute of Health, Bethesda, MA).
Migration assay
In vitro migration assay was performed using Costar Transwell
inserts (Pore size: 8 mm; Corning, Albany, NY) in 24-well plates as
described previously [48–50]. Approximately 1 6 104 cells in
200 ml of serum-free medium were placed in the upper chamber,
and 300 ml of the same medium containing ATP was placed in the
lower chamber. Before performing the migration assay, cells were
pre-treated for 60 min with nicardipine followed by treatment
with ATP during the 24-h migration assay (incubated at 37uC in
5% CO2). After the 24-h assay, the cells were stained with 0.05%
crystal violet and 2% methanol. Non-migratory cells on the upper
surface of the filters were removed by wiping with a cotton swab.
Cell number was counted in five random fields per well under a
microscope at 2006magnification. Images of migratory cells were
Figure 1. Effect of nicardipine on ATP-induced microglial cell migration. (A) Cell viability following nicardipine treatment in BV-2 microglia.
Cells were treated with concentrations ranging from 1 to 10 mM of nicardipine for 24 h, and cell viability was measured by the MTT assay. The results
are expressed as mean 6 S.E.M. of three independent experiments. (B) Cells were pre-incubated with or without nicardipine (10 mM) for 60 min
followed by a 24-h treatment with ATP (100 or 300 mM). In vitro migratory activities were examined using a cell culture insert system. The results are
expressed as mean 6 S.E.M. from 4 to 5 independent experiments. *, p,0.05 compared with the control group; #, p,0.05 compared with the ATP
(300 mM) alone. (C) The migrated cells were visualized by phase-contrast imaging.
doi:10.1371/journal.pone.0091167.g001
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observed and acquired using a digital camera and light micro-
scope.
Quantitative real-time PCR
Quantitative real-time PCR was performed according to our
previous report [51]. Briefly, quantitative real-time PCR using
SYBR Green Master Mix was performed with StepOne Plus
System (Applied Biosystems, Singapore). After incubation at 50uC
for 2 min and 95uC for 10 min, the PCR was performed as
follows: 40 cycles at 95uC for 10 s and 60uC for 1 min. The
threshold was set above the non-template control background and
within the linear phase of target gene amplification to calculate the
cycle number at which the transcript was detected (denoted as
CT).
Nitric oxide assay
Production of nitric oxide was assayed by measuring nitrite
levels, the stable product of nitric oxide, in the culture medium, as
described in our previous report [52]. Briefly, the accumulated
nitrite in the medium was determined by a colorimetric assay with
a Griess reaction. The culture supernatant reacted with an equal
volume of Griess reagent (0.1% naphthylethylenediamine and 1%
sulfanilamide in 5% H3PO4). After 10 min at room temperature in
the dark, the absorbance was determined at 550 nm using a
microplate reader (Thermo Scientific, Vantaa, Finland).
MTT assay
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-
yl)-2,5- diphenyltetrazolium bromide (MTT) assay [53]. After
treatment with nicardipine for 24 h, cell culture media were
removed and washed with PBS. MTT (0.5 mg/ml) was added to
each culture well and the mixture was incubated for 2 h at 37 uC.
The MTT reagent was then replaced with DMSO (100 ml per
well) to dissolve formazan crystals. After the mixture was shaken at
room temperature for 10 min, absorbance was determined at
550 nm using a microplate reader (Thermo Scientific, Vantaa,
Finland).
Statistical analyses
The values are reported as mean 6 S.E.M. Statistical analyses
for two groups were performed using Student’s t-test. Statistical
comparisons of more than two groups were performed using one-
way ANOVA with Bonferroni’s post-hoc test. The difference was
determined to be significant if the p value was ,0.05.
Results
Nicardipine suppresses neuroinflammatory responses in
microglial cells
We used BV-2 microglia to study the effects of nicardipine on
neuroinflammatory responses. Concentrations ranging from 1 to
10 mM nicardipine were used. A colorimetric cell viability assay
(MTT) confirmed that these concentrations did not affect cell
viability (Fig. 1A). Nicardipine inhibited an ATP-induced increase
in BV-2 microglial migratory activity (Fig. 1B). Representative
micrographs of migrating cells are shown in Fig. 1C. Notably,
nicardipine treatment alone did not affect baseline cell migratory
activity. To determine the effect of nicardipine on nitric oxide
production, cells were treated with different concentrations of
nicardipine (1 to 10 mM) and were stimulated with LPS plus IFN-
c. The cell culture medium was then collected to determine the
nitrite content. We have previously demonstrated that peptido-
glycan, a component of the Gram-positive bacterium cell wall,
causes neuroinflammation in microglia [54,55]. Hence, to further
determine the effect of nicardipine on nitric oxide production, BV-
2 microglia were also stimulated with peptidoglycan. As shown in
Fig. 2A and 2B, nicardipine effectively inhibited nitric oxide
production in a concentration-dependent manner following
exposure to either LPS (10ng/ml) plus IFN-c (10ng/ml) or
peptidoglycan (10 mg/ml). In addition, the inhibition of nitric
oxide production initiated at 3,5 mM achieved a maximum at
10 mM. The levels of iNOS expression were detected by western
blotting. Nicardipine also reduced LPS/IFN-c- and peptidogly-
can-induced iNOS expression (Fig. 3A and 3C, respectively) and
COX-2 expression in a concentration-dependent manners (Fig. 3B
and 3D). Notably, nicardipine treatment alone did not affect
iNOS, COX-2 and nitric oxide expression. We further analyzed
the expression of inflammatory mediators by real-time PCR. BV-2
microglia were treated with different concentrations of nicardipine
(1 to 10 mM) and stimulated with LPS plus IFN-c for 6 h.
Nicardipine potentiates a concentration-dependent suppression of
iNOS and COX-2 when stimulating BV-2 with LPS/IFN-c
Figure 2. Inhibitory effect of nicardipine on LPS/IFN-c or peptidoglycan-stimulated nitric oxide production. BV-2 microglial cells were
pretreated with different concentrations of nicardipine (1, 3, 5, or 10 mM) for 60 min before application of LPS (10 ng/ml) plus IFN-c (10 ng/ml) (A) or
peptidoglycan (10 mg/ml; B) for another 24 h. The culture media were collected and analyzed by a Griess reaction. Nitric oxide production is
significantly different between the LPS/IFN-c (or peptidoglycan) treatment alone and the LPS/IFN-c (or peptidoglycan) treatment with nicardipine
groups (one-way ANOVA followed by Bonferroni’s post hoc test). The results are expressed as mean 6 S.E.M. from 3 to 4 independent experiments.
*, p,0.05 compared with the control group; #, p,0.05 compared with the LPS/IFN-c or peptidoglycan treatment.
doi:10.1371/journal.pone.0091167.g002
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(Fig. 4A and 4B). Similarly, treatment with nicardipine also
inhibited LPS/IFN-c-induced IL-6 and IL-1b expression in a
concentration-dependent manner (Fig. 4C and 4D, respectively).
These results indicate that nicardipine exerts anti-inflammatory
effects on microglial cells.
Regulatory effects of nicardipine on signaling pathways
We further studied the signaling pathways involved in the
inhibitory effects of nicardipine on neuroinflammation in microg-
lia. MAP kinase and PI3 kinase/Akt are the most important
signaling pathways in the regulation of inflammatory responses in
macrophages and microglia [56–58]. We examined whether MAP
kinase activation is modulated by nicardipine in microglia. BV-2
Figure 3. Inhibitory effect of nicardipine on LPS/IFN-c- or peptidoglycan-stimulated iNOS and COX-2 expressions. (A and B) BV-2
microglial cells were pretreated with different concentrations of nicardipine (1, 3, 5, or 10 mM) for 60 min before application of LPS (10 ng/ml) plus
IFN-c (10 ng/ml) for another 24 h. (C and D) Cells were pretreated with different concentrations of nicardipine (1, 3, 5, or 10 mM) for 60 min before
application of peptidoglycan (10 mg/ml) for another 24 h. Western blot analysis for iNOS (A and C) and COX-2 (B and D) expression was performed on
whole cell lysates. The quantitative results are shown in the bottom panels. iNOS expression was significantly different between the LPS/IFN-c (or
peptidoglycan) treated-group and the group treated LPS/IFN-c (or peptidoglycan) with nicardipine (one-way ANOVA followed by Bonferroni’s post
hoc test). COX-2 expression was significantly different between the LPS/IFN-c (or peptidoglycan) treated- group and the LPS/IFN-c (or peptidoglycan)
with nicardipine treated- group (one-way ANOVA followed by Bonferroni’s post hoc test). The results are expressed as mean 6 S.E.M. from 4 to 5
independent experiments. *, p,0.05 compared with the LPS/IFN-c or peptidoglycan treatment.
doi:10.1371/journal.pone.0091167.g003
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microglia were treated with nicardipine and then stimulated with
LPS plus IFN-c for 60 min. Western blot analysis for phospho-
ERK, phospho-p38, phospho-JNK, or phospho-Akt was per-
formed on whole cell lysates. As shown in Fig. 5A, nicardipine
inhibited LPS/IFN-c-induced p38 and Akt expression but not
ERK and JNK. Additionally, nicardipine at 10 mM did not affect
LPS/IFN-c-induced MAP kinase and Akt phosphorylation.
Expressions of inflammatory mediators are mainly regulated by
the transcription factors NF-kB and AP-1 in microglia [52,59]. As
shown in Fig. 5B, LPS plus IFN-c treatment increased p65 and
cJun activation in BV-2 microglia after 90 min. The increases in
p65 and cJun activation following LPS/IFN-c treatment were
attenuated by nicardipine treatment.
Nicardipine inhibits proinflammatory cytokine expression
in mouse brain microglia
We next examined whether nicardipine suppresses markers of
microglial activation in vivo. Mice first received intraperitoneal
injections of saline or nicardipine for 3 consecutive days, followed
by an intraperitoneal injection of LPS 2 h after injected with saline
or nicadipine on the third day. Twenty-four hours later, expression
of surface CD11b/CD45 and intracellular IL-6 and TNF-a were
determined by flow cytometry. As shown in Fig. 6A, the
representative bivariate dot plots of Percoll-isolated microglia
stained with CD11b+ and CD45low confirmed the presence of this
subset of microglia in mice receiving either LPS or co-treatment of
nicardipine and LPS. The mean fluorescence intensity (M.F.I)
reflecting intracellular IL-6 and TNF-a expression by microglia
were reduced in the brains of mice that received LPS with
nicardipine treatment (Fig. 6B and 6C).
Nicardipine inhibits microglial activation in a mouse
model
To determine the improvements induced by nicardipine
treatment on neuroinflammatory responses in vivo, we performed
an immunohistochemical analysis on microglia. The clinical dose
of nicardipine administration used for managing blood pressure is
approximately 5 mg/kg [60]. Mice were continuously adminis-
tered nicardipine at a dose of 5 or 50 mg/kg daily for 3 days, and
were then injected with or without LPS. The activation of
microglia was assessed morphologically by immunohistochemistry
with the well-characterized Iba-1-specific antibody. Twenty-four
hours after LPS injection, microglial activation was observed to be
homogeneously distributed throughout the cortical, hippocampal
and striatal regions. The Iba-1 immunolabeling was more intense
in LPS-treated BV2 depicted with enlarger cell bodies and
retracted processes compared with the control group (Fig. 7).
Furthermore, LPS injection induced pronounced hypertrophy of
cortical, hippocampal and striatal microglial cells. Microglial
activation in the mouse brain was effectively attenuated by
administration of nicardipine (Fig. 7). In addition, administration
of nicardipine (50 mg/kg) alone did not affect microglia activation.
Figure 4. Nicardipine suppresses the expression of inflammatory mediators in BV-2 microglial cells. Cells were pretreated with different
concentrations of nicardipine (1, 5, or 10 mM) for 60 min, then challenged with LPS (10 ng/ml) plus IFN-c (10 ng/ml) for another 6 h. The expression
of iNOS, COX-2, IL-6, and IL-1b (A, B, C and D respectively) were determined by real-time PCR. Cytokine expression was significantly different between
the LPS/IFN-c alone and the LPS/IFN-c with nicardipine groups (one-way ANOVA followed by Bonferroni’s post hoc test). The results are expressed as
mean6 S.E.M. from 3 to 4 independent experiments. *, p,0.05 compared with the control group;#, p,0.05 compared with the LPS/IFN-c treatment
alone group.
doi:10.1371/journal.pone.0091167.g004
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Discussion
Nicardipine, a second-generation dihydropyridine-type calcium
channel blocker, is the most frequently used anti-hypertensive
agent following acute brain injury [26,28,31,61-63]. Nifedipine
and nimodipine are also established dihydropyridine-type calcium
channel blockers. The protective effects of nimodipine have been
evidenced by animal models of ischemic brain [64]. Previous
studies have also reported that nicardipine can protect against
hypertension-related brain damage [32–34]. Nifedipine has been
reported to inhibit the expression of inflammatory and fibrogenic
responses in advanced glycation end product-exposed fibroblasts
[65]. The existence of calcium channels in glial cells is still
controversial [66,67]. Interestingly, the L-type calcium channel
blockers nimodipine and verapamil, which have been reported to
confer neuroprotective effects, and inhibit microglial activation
[68]. Indeed, recent studies have reported that nimodipine and
verapamil exert their neuroprotective effects through anti-
neuroinflammatory properties [38,69]. The anti-inflammatory
effect of nimodipine has also been indicated to down-regulate
TNF-a and IL-1b expression in the hippocampus [70] and IL-1b
expression in microglia [39]. Importantly, the clinical dose of
nicardipine used for managing blood pressure is approximately
5 mg/kg [60]. Here, we also found that 5 mg/kg of nicardipine
inhibits microglia activation in our in vivo mouse model, but
50 mg/kg did not produce a more potent inhibitory response.
Cytokines are important mediators involved in immune,
inflammatory, and immunomodulatory functions [71]. Although
inflammatory responses are necessary for normal neuronal cell
functions, microglial activation must be tightly regulated to avoid
exaggerated responses and extended nenurotoxicity [24,72].
Bacterial meningitis is the most frequently fatal infection in
CNS, which results in significant neurological sequelae [73,74]. In
Gram-negative infections, LPS is a well-known activator of
microglia. Peptidoglycan and lipoteichoic acid, the major compo-
nents of the Gram-positive bacterium cell wall, activate microglia
and induce the release of chemokines and cytokines [52,54,55].
Activated microglia migrate to the injury site and express
inflammatory mediators, such as iNOS and COX-2, and these
proinflammatory cytokines have been shown to result in neuronal
damage [13–16]. In the present study, nicardipine effectively
reduced cell migration of microglia induced by ATP, and
proinflammatory cytokine expression activated by both LPS plus
IFN-c and peptidoglycan. Calcium channel blockers have been
reported to act through a calcium channel-independent mecha-
nism on multiple signaling molecules, including nuclear factor-
kappa B [70,75] and STAT3 [68]. Our present results and
previous reports suggest that the neuroprotective effects of the
calcium channel blocker nicardipine are mediated by a calcium
channel-independent anti-neuroinflammatory effect.
Numerous lines of evidence support that MAP kinase and PI3
kinase/Akt are the most important signaling pathways to regulate
inflammatory responses in microglia [52,56,58,76]. Pro-inflam-
matory cytokines (e.g., interferon or interleukin) could activate
microglial cells and trigger several inflammatory signaling
pathways, including AP-1, Akt, NF-kB and MAP kinase. Here,
we also report that nicardipine reduced the activation of the
proinflammatory transcription factors NF-kB and AP-1. Nicardi-
pine also inhibited LPS/IFN-c-induced p38 and Akt activation in
microglial cells. Our results also showed that nicardipine can
inhibit microglial activation and intracellular expression of IL-6
and TNF-a in vivo. The results of current study suggest that
nicardipine can exert anti-neuroinflammatory responses in
microglia, which is unlikely to be mediated by blockade of
calcium channels. The roles of calcium channels on microglia have
led to considerable debate as to whether calcium buffering
Figure 5. Nicardipine suppresses LPS/IFN-c-induced signaling pathways. BV-2 microglial cells were pretreated with nicardipine (10 mM) for
60 min, then exposed to LPS (10 ng/ml) plus IFN-c (10 ng/ml) for another 60 min. Western blot analysis was performed on whole cell lysates, and the
signal intensities were normalized to total protein expression. The results are expressed as mean 6 S.E.M. from 3 to 4 independent experiments.
*, p,0.05 compared with the LPS/IFN-c treatment alone group.
doi:10.1371/journal.pone.0091167.g005
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Figure 6. LPS-induced intracellular IL-6 and TNF-a expression on microglia is reduced by nicardipine. Mice received intraperitoneal
injections of saline or nicardipine (5 mg/kg) for 3 consecutive days. On the third day, 2 h after injection of saline or nicardipine, mice were injected
with LPS (5 mg/kg) and housed for another 24 h. (A) Representative bivariate dot plots of Percoll-isolated microglial cells stained with anti-CD11b-
FITC and anti-CD45-PerCP-Cy5.5. Microglia were identified by CD11b+/CD45low staining. Representative histograms of intracellular IL-6 (B) and TNF-a
(C) expression in isolated microglia. Mean fluorescence intensity (M.F.I.) of intracellular IL-6 and TNF-a expressed by CD11b+/CD45low microglia
following experimental treatments.
doi:10.1371/journal.pone.0091167.g006
Figure 7. Nicardipine prevents LPS-induced microglial activation. Mice received intraperitoneal injections of nicardipine at concentrations
of either 5 mg/kg or 50 mg/kg, once per day, for 3 consecutive days. On the third day, nicardipine treatment was followed with a single
intraperitoneal injection of LPS (20 mg/kg). Microglial morphology was visualized by anti-Iba-1 immunolabeling and DAB (n = 5 each group).
doi:10.1371/journal.pone.0091167.g007
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participates in neuroinflammatory responses, as calcium has been
conceived to be physically relevant. However, the current findings
offer new insights for developing therapeutic approaches to treat
neuronal cell death and neuroinflammation-related disorders.
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